MiR-320e is a novel prognostic biomarker in colorectal cancer

L. Perez-Carbonell, Frank A Sinicrope, Steven Robert Alberts, Ann L Oberg, F. Balaguer, A. Castells, C. R. Boland, A. Goel

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Advances in early detection and treatment have improved outcomes in patients with colorectal cancer (CRC). However, there remains a need for robust prognostic and predictive biomarkers. We conducted a systematic discovery and validation of microRNA (miRNA) biomarkers in two clinical trial cohorts of CRC patients.Methods:We performed an initial 'discovery' phase using Affymetrix miRNA expression arrays to profile stage III CRC patients with and without tumour recurrence (n=50 per group) at 3-years of follow-up. All patients received adjuvant 5-fluorouracil (5-FU) plus oxaliplatin, that is, FOLFOX, treatment. During 'validation', we analysed miRNAs using qRT-PCR in an independent cohort of 237 stage II-IV CRC patients treated with 5-FU-based chemotherapy, as well as in normal colonic mucosa from 20 healthy subjects. Association with disease recurrence, disease-free survival (DFS) and overall survival (OS) was examined using Cox proportional hazard models.Results:In the discovery cohort, miR-320e expression was significantly elevated in stage III colon cancers from patients with vs without recurrence (95% confidence interval (CI)=1.14-1.42; P

Original languageEnglish (US)
Pages (from-to)83-90
Number of pages8
JournalBritish Journal of Cancer
Volume113
Issue number1
DOIs
StatePublished - Jun 30 2015

Fingerprint

Colorectal Neoplasms
Biomarkers
MicroRNAs
oxaliplatin
Recurrence
Fluorouracil
Proportional Hazards Models
Colonic Neoplasms
Disease-Free Survival
Healthy Volunteers
Mucous Membrane
Clinical Trials
Confidence Intervals
Drug Therapy
Polymerase Chain Reaction
Survival
Therapeutics
Neoplasms

Keywords

  • 5-fluorouracil
  • biomarker
  • colorectal cancer
  • expression
  • Micrornas
  • prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

MiR-320e is a novel prognostic biomarker in colorectal cancer. / Perez-Carbonell, L.; Sinicrope, Frank A; Alberts, Steven Robert; Oberg, Ann L; Balaguer, F.; Castells, A.; Boland, C. R.; Goel, A.

In: British Journal of Cancer, Vol. 113, No. 1, 30.06.2015, p. 83-90.

Research output: Contribution to journalArticle

Perez-Carbonell, L. ; Sinicrope, Frank A ; Alberts, Steven Robert ; Oberg, Ann L ; Balaguer, F. ; Castells, A. ; Boland, C. R. ; Goel, A. / MiR-320e is a novel prognostic biomarker in colorectal cancer. In: British Journal of Cancer. 2015 ; Vol. 113, No. 1. pp. 83-90.
@article{21226149e2c04317ab75880ff9bdeb4a,
title = "MiR-320e is a novel prognostic biomarker in colorectal cancer",
abstract = "Advances in early detection and treatment have improved outcomes in patients with colorectal cancer (CRC). However, there remains a need for robust prognostic and predictive biomarkers. We conducted a systematic discovery and validation of microRNA (miRNA) biomarkers in two clinical trial cohorts of CRC patients.Methods:We performed an initial 'discovery' phase using Affymetrix miRNA expression arrays to profile stage III CRC patients with and without tumour recurrence (n=50 per group) at 3-years of follow-up. All patients received adjuvant 5-fluorouracil (5-FU) plus oxaliplatin, that is, FOLFOX, treatment. During 'validation', we analysed miRNAs using qRT-PCR in an independent cohort of 237 stage II-IV CRC patients treated with 5-FU-based chemotherapy, as well as in normal colonic mucosa from 20 healthy subjects. Association with disease recurrence, disease-free survival (DFS) and overall survival (OS) was examined using Cox proportional hazard models.Results:In the discovery cohort, miR-320e expression was significantly elevated in stage III colon cancers from patients with vs without recurrence (95{\%} confidence interval (CI)=1.14-1.42; P",
keywords = "5-fluorouracil, biomarker, colorectal cancer, expression, Micrornas, prognosis",
author = "L. Perez-Carbonell and Sinicrope, {Frank A} and Alberts, {Steven Robert} and Oberg, {Ann L} and F. Balaguer and A. Castells and Boland, {C. R.} and A. Goel",
year = "2015",
month = "6",
day = "30",
doi = "10.1038/bjc.2015.168",
language = "English (US)",
volume = "113",
pages = "83--90",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - MiR-320e is a novel prognostic biomarker in colorectal cancer

AU - Perez-Carbonell, L.

AU - Sinicrope, Frank A

AU - Alberts, Steven Robert

AU - Oberg, Ann L

AU - Balaguer, F.

AU - Castells, A.

AU - Boland, C. R.

AU - Goel, A.

PY - 2015/6/30

Y1 - 2015/6/30

N2 - Advances in early detection and treatment have improved outcomes in patients with colorectal cancer (CRC). However, there remains a need for robust prognostic and predictive biomarkers. We conducted a systematic discovery and validation of microRNA (miRNA) biomarkers in two clinical trial cohorts of CRC patients.Methods:We performed an initial 'discovery' phase using Affymetrix miRNA expression arrays to profile stage III CRC patients with and without tumour recurrence (n=50 per group) at 3-years of follow-up. All patients received adjuvant 5-fluorouracil (5-FU) plus oxaliplatin, that is, FOLFOX, treatment. During 'validation', we analysed miRNAs using qRT-PCR in an independent cohort of 237 stage II-IV CRC patients treated with 5-FU-based chemotherapy, as well as in normal colonic mucosa from 20 healthy subjects. Association with disease recurrence, disease-free survival (DFS) and overall survival (OS) was examined using Cox proportional hazard models.Results:In the discovery cohort, miR-320e expression was significantly elevated in stage III colon cancers from patients with vs without recurrence (95% confidence interval (CI)=1.14-1.42; P

AB - Advances in early detection and treatment have improved outcomes in patients with colorectal cancer (CRC). However, there remains a need for robust prognostic and predictive biomarkers. We conducted a systematic discovery and validation of microRNA (miRNA) biomarkers in two clinical trial cohorts of CRC patients.Methods:We performed an initial 'discovery' phase using Affymetrix miRNA expression arrays to profile stage III CRC patients with and without tumour recurrence (n=50 per group) at 3-years of follow-up. All patients received adjuvant 5-fluorouracil (5-FU) plus oxaliplatin, that is, FOLFOX, treatment. During 'validation', we analysed miRNAs using qRT-PCR in an independent cohort of 237 stage II-IV CRC patients treated with 5-FU-based chemotherapy, as well as in normal colonic mucosa from 20 healthy subjects. Association with disease recurrence, disease-free survival (DFS) and overall survival (OS) was examined using Cox proportional hazard models.Results:In the discovery cohort, miR-320e expression was significantly elevated in stage III colon cancers from patients with vs without recurrence (95% confidence interval (CI)=1.14-1.42; P

KW - 5-fluorouracil

KW - biomarker

KW - colorectal cancer

KW - expression

KW - Micrornas

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=84934440829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934440829&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.168

DO - 10.1038/bjc.2015.168

M3 - Article

VL - 113

SP - 83

EP - 90

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -